S&P 500   3,120.81 (-0.04%)
DOW   27,951.48 (-0.30%)
QQQ   203.45 (+0.19%)
BABA   184.16 (-0.24%)
ACB   2.34 (+2.64%)
F   8.93 (-0.22%)
BAC   32.92 (-0.12%)
DIS   149.03 (+0.93%)
S&P 500   3,120.81 (-0.04%)
DOW   27,951.48 (-0.30%)
QQQ   203.45 (+0.19%)
BABA   184.16 (-0.24%)
ACB   2.34 (+2.64%)
F   8.93 (-0.22%)
BAC   32.92 (-0.12%)
DIS   149.03 (+0.93%)
S&P 500   3,120.81 (-0.04%)
DOW   27,951.48 (-0.30%)
QQQ   203.45 (+0.19%)
BABA   184.16 (-0.24%)
ACB   2.34 (+2.64%)
F   8.93 (-0.22%)
BAC   32.92 (-0.12%)
DIS   149.03 (+0.93%)
S&P 500   3,120.81 (-0.04%)
DOW   27,951.48 (-0.30%)
QQQ   203.45 (+0.19%)
BABA   184.16 (-0.24%)
ACB   2.34 (+2.64%)
F   8.93 (-0.22%)
BAC   32.92 (-0.12%)
DIS   149.03 (+0.93%)
Log in

Sanofi Stock Price, Forecast & Analysis (NYSE:SNY)

$46.02
-0.69 (-1.48 %)
(As of 11/19/2019 12:40 PM ET)
Today's Range
$45.94
Now: $46.02
$46.42
50-Day Range
$44.34
MA: $45.76
$47.20
52-Week Range
$40.00
Now: $46.02
$47.47
Volume419,832 shs
Average Volume1.31 million shs
Market Capitalization$115.24 billion
P/E Ratio14.70
Dividend Yield2.52%
Beta0.67
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$39.60 billion
Cash Flow$5.06 per share
Book Value$26.11 per share

Profitability

Net Income$4.28 billion

Miscellaneous

EmployeesN/A
Outstanding Shares2,504,138,000
Market Cap$115.24 billion
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.


Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi declared an annual dividend on Tuesday, February 26th. Stockholders of record on Wednesday, May 8th will be given a dividend of $1.7395 per share on Friday, May 31st. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) issued its quarterly earnings results on Wednesday, October, 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.98 by $0.09. The firm earned $9.39 billion during the quarter, compared to the consensus estimate of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm's revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. View Sanofi's Earnings History.

When is Sanofi's next earnings date?

Sanofi is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Sanofi.

What price target have analysts set for SNY?

7 brokers have issued 12-month target prices for Sanofi's stock. Their forecasts range from $52.00 to $52.00. On average, they expect Sanofi's stock price to reach $52.00 in the next twelve months. This suggests a possible upside of 13.0% from the stock's current price. View Analyst Price Targets for Sanofi.

What is the consensus analysts' recommendation for Sanofi?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:
  • 1. According to Zacks Investment Research, "Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging. Sanofi’s Specialty Care segment, particularly, is on a strong footing with recent FDA approvals of new drugs Libtayo and Cablivi, and Dupixent for its second indication in asthma. Dupixent could prove to be an important growth driver. The performance of the Vaccines and Consumer Healthcare franchises has also improved of late. Sanofi’s R&D pipeline is strong and it has delivered important results with several positive data read-outs and the achievement of regulatory milestones this year. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares have outperformed the industry in the past six months." (8/29/2019)
  • 2. HC Wainwright analysts commented, "We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 7.3% discount rate and 22% effective tax rate. Our assumptions assign a 90% probability of launch to DARZALEX in smoldering MM." (2/28/2019)

Has Sanofi been receiving favorable news coverage?

Media stories about SNY stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sanofi earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Sanofi.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), AT&T (T), Bank of America (BAC), Merck & Co., Inc. (MRK), Exxon Mobil (XOM), AbbVie (ABBV), Alibaba Group (BABA), General Electric (GE) and Pfizer (PFE).

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.69%), Hamlin Capital Management LLC (0.07%), St. James Investment Company LLC (0.05%), First Trust Advisors LP (0.04%), Managed Asset Portfolios LLC (0.02%) and Janney Capital Management LLC (0.02%). View Institutional Ownership Trends for Sanofi.

Which major investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including CORDA Investment Management LLC., Hamlin Capital Management LLC, Russell Investments Group Ltd., SG Americas Securities LLC, Crossmark Global Holdings Inc., Janney Capital Management LLC, Oppenheimer Asset Management Inc. and Commonwealth Equity Services LLC. View Insider Buying and Selling for Sanofi.

Which major investors are buying Sanofi stock?

SNY stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, First Trust Advisors LP, St. James Investment Company LLC, Managed Asset Portfolios LLC, CWM LLC, Envestnet Asset Management Inc., Premier Asset Management LLC and Stephens Inc. AR. View Insider Buying and Selling for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $46.02.

How big of a company is Sanofi?

Sanofi has a market capitalization of $115.24 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. View Additional Information About Sanofi.

What is Sanofi's official website?

The official website for Sanofi is http://www.sanofi.com/.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]


MarketBeat Community Rating for Sanofi (NYSE SNY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  442 (Vote Outperform)
Underperform Votes:  545 (Vote Underperform)
Total Votes:  987
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel